Gastroenterología y Reumatología, Hospital Internacional de Colombia, Bucaramanga, Colombia; Grupo de Inmunología Celular y Molecular (INMUBO), Universidad El Bosque, Bogotá, Colombia; Gastroadvanced IPS, Bogotá, Colombia.
Medicina interna, Universidad de La Sabana, Chía, Cundinamarca, Colombia.
Gastroenterol Hepatol. 2024 Jun-Jul;47(6):582-590. doi: 10.1016/j.gastrohep.2023.10.003. Epub 2023 Oct 6.
Tofacitinib is indicated in patients with moderate to severe ulcerative colitis (UC); however, given its rapid onset of action, it may constitute an alternative in patients with hospitalized severe acute UC. There are few data on this indication in the literature. The aim of this study was to describe the efficacy and safety of tofacitinib in the management of patients with hospitalized UC, as well as its clinical characteristics and other treatment patterns.
Descriptive observational study of adults and children with CUAG treated with tofacitinib between June 2019 and December 2022 in Colombia. Sociodemographic and clinical variables were collected, therapeutic response was evaluated in different periods of time and descriptive analysis of quantitative and qualitative variables was performed.
Six patients (five adults and one pediatric), mean age 33.2 (SD: 8.5) years, with CUAG. Symptom remission was obtained in 100% of patients at day 7 after tofacitinib initiation. In three patients information was obtained beyond 6 months, with 100% clinical, biochemical, and endoscopic remission and without requiring colectomy. In the case of the pediatric patient, symptom remission was achieved one week after starting tofacitinib, remaining in clinical, biochemical and endoscopic remission beyond 6 months. No serious adverse events were reported in any of the cases.
Tofacitinib represents a rescue therapeutic alternative in CUAG, with rapid clinical response, adequate tolerance and less need for colectomy, being sustained for periods beyond 6 months.
托法替布适用于中重度溃疡性结肠炎（UC）患者；然而，鉴于其起效迅速，它可能成为住院重度急性 UC 患者的替代选择。关于该适应证的文献数据较少。本研究旨在描述托法替布在管理住院 UC 患者中的疗效和安全性，以及其临床特征和其他治疗模式。
这是一项在哥伦比亚于 2019 年 6 月至 2022 年 12 月期间对接受托法替布治疗的 CUAG 成人和儿童进行的描述性观察研究。收集了社会人口统计学和临床变量，评估了不同时间段的治疗反应，并对定量和定性变量进行了描述性分析。
共纳入 6 名患者（5 名成人和 1 名儿科患者），平均年龄为 33.2（SD：8.5）岁，均患有 CUAG。托法替布治疗 7 天后，100%的患者症状缓解。在 3 名患者中，获得了超过 6 个月的信息，100%的患者在临床、生化和内镜方面缓解，且无需接受结肠切除术。儿科患者在开始托法替布治疗一周后症状缓解，在超过 6 个月的时间里保持临床、生化和内镜缓解，无严重不良事件报告。
托法替布是 CUAG 的一种挽救性治疗选择，具有快速的临床反应、良好的耐受性和较少需要结肠切除术，在超过 6 个月的时间里持续缓解。
